Contribution of Skin Color in Stabilization of Active Cases of Vitiligo by Narrow Band UVB

Vitiligo Clinical Trial

Official title:

The Reflection of Skin Color on the Efficacy of Narrow Band UVB in Stabilization of Active Cases of Vitiligo

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04030988
• Other study ID #: u4xjkivz
• Status: Recruiting
• Phase: Phase 1
• Start date: November 1, 2018
• Est. completion date: November 2019

Study information

• Verified date: July 2019
• Source: Ain Shams University
• Contact: Mahy ElBassiouny, Ass.Lecturer
• Phone: 002 01002202651
• Email: mahyelbasyouni[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Vitiligo is a disease in which autoimmunity plays a major role. Multiple treatment options are available, of which narrow-band UVB is a cornerstone, acting through immunosuppression and repigmentation by stimulating reservoir melanocytes.

It's expected that this immunsupression is lower in darker skin types, where increased basal melanin might act as a barrier.

Description:

Vitiligo is acquired depigmentation disorder. Several theories were hypothesized for causing vitiligo, of which the autoimmune theory is the most accepted.

The main targets of therapy are stabilization of the disease activity through immunosuppression, and repigmentation through stimulation of reservoir melanocytes proliferation and migration.

Narrow band ultraviolet phototherapy (NB-UVB) remains the cornerstone treatment of vitiligo. NB-UVB can induce both immunosuppression and repigmentation. Several factors can modulate the efficacy of NB-UVB therapy in treatment of vitiligo cases, including patient's age, lesion site, duration of the disease, and duration of the therapy.

The immunosuppressive function of NB-UVB was first detected in 1963 by Hanisko and Suskind, who observed that the contact hypersensitivity response in skin sensitized to dinitrochlorobenzene (DNCB) was reduced if skin was previously exposed to suberythemal doses of UVB.

Present evidence suggests that UVB suppress immune system through generation of T-suppressor cells, which inhibit the effector cells of Th1 type. It appears that UV-induced immunosuppression depresses the function of Th1 cells and enhances the activity of Th2 cells via cytokines such as Interleukin 10.

It's expected that this immunsupression is lower in darker skin types, where increased basal melanin might act as a barrier. However, skin was previously divided to UVB-resistant and UVB-sensitive (UVB-R and UVB-S) based on the contact hypersensitivity testing, regardless of the skin type. Moreover, A study on NB-UVB phototherapy for psoriasis revealed that photoadaptation during NB-UVB therapy Is Independent of skin type.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: November 2019
• Est. primary completion date: September 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 60 Years

Eligibility

Inclusion Criteria:

• Active cases of non-segmental vitiligo, VIDA +2 or more.

• All skin types

• Age above 6 years, both sexes.

Exclusion Criteria:

• Contraindications to NB-UVB ( photosensitive skin disorders, skin malignancy, patients on photosensitizing medications)

• Contraindications to mini-pulse steroid therapy (uncontrolled diabetes or hypertension, peptic ulcer)

• Stable disease (VIDA 0 & -1) and activity more than 6 months ago (VIDA +1).

• The use of other treatment for vitiligo during the 3 months previous to enrollment.

Related Conditions & MeSH terms

• Vitiligo

Intervention

Drug:
• Oral dexamethasone minipulse
50 patients will receive mini pulse dexamethasone therapy in a dose of 3 mg/ day for adults or 1.5 mg/day for children on two consecutive days per week plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments.
• Placebo oral tablet
50 patients will receive placebo having the same color, form and packaging as the dexamethasone therapy for 6 months plus NB-UVB phototherapy at starting dose of 0.3 J/cm2, at a rate of 3 times per week for 6 months (72 sessions) with gradually increasing increments

Locations

Country	Name	City	State
Egypt	Ain Shams University	Cairo	Abbaseya

Sponsors (6)

Lead Sponsor	Collaborator
Ain Shams University	Alexandria University, Assiut University, Cairo University, Menia University, Suez Canal University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detecting number of participants with clinical activity of vitiligo	Appearance of new lesions or expansion of pre-existing lesions by clinical examination.	At 6 months after treatment.
Primary	Photography to detect activity of vitiligo	New lesions in each area will be counted.	Change from baseline (first visit) at 6 months after treatment.
Primary	Elevation of serum Vitiligo activity markers.	A 5 cc blood sample will be withdrawn from each patient for: ELISA assessment of CXCL-10 (Pg/ml)	Change from baseline at 6 months after treatment.
Primary	Elevation of PCR levels of serum Vitiligo activity markers	A 5 cc blood sample will be withdrawn from each patient for: PCR assessment of m-RNA of CXCL-10 as markers of disease activity.	Change from baseline at 6 months after treatment.